Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Balancing Risk Post-PCI
Published: 13 October 2022
18m 3sPart 1 Clinical Vignette and Panel Discussion Marco Valgimigli, Roxana Mehran, Dominick J Angiolillo, Pascal Vranckx
13m 35sPart 2 Assessing Bleeding Risk Post-PCI Roxana Mehran
15m 52sPart 3 Optimum Duration of DAPT: Overview of Current Data Dominick J Angiolillo
This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.
The third broadcast in this series, focused on Balancing Risk Post-PCI. In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.
Prof Roxana Mehran (Mount Sinai Hospital, New York, US) chairs the proceedings, and is joined by Prof Dominick Angiolillo (University of Florida College of Medicine-Jacksonville, US), Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH) and Prof Pascal Vranckx (University of Hasselt, BE) for a series of insightful presentations and discussions.
You can also catch up on other broadcasts in this series:
Key Learning Objectives
Following the completion of this programme, physicians will be in a position to:
- Apply the use of validated bleeding risk tools across a wide range of patients
- Use guidelines and clinical judgement to select antiplatelet therapy regimens in patients at elevated bleeding risk
- Recall the clinical significance of trial data assessing truncated periods of DAPT
- Prescribe confidently in patients judged to be at elevated bleeding risk
- Recall the safety profiles of different P2Y12 inhibitors
- General Cardiologists
- Interventional Cardiologists
- Nurses and any other allied HCPs
More from this programme
Clinical Vignette and Panel Discussion
Assessing Bleeding Risk Post-PCI
Optimum Duration of DAPT: Overview of Current Data
Bleeding Risk Mitigation - Safety in Clinical Practice and Panel Discussion
Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services
Prof Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium, and Professor of Medicine at the University of Hasselt, Belgium.
Prof Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands.